Novartis Commits To Increase Patient Reach; Enhances Full Carbon Neutrality Target

Novartis said it has committed to increase patient reach with its strategic medicines by at least 200% by 2025, as part of its ambition to expand access to medicines in low- and middle-income countries or LMICs.

In addition, the company plans to increase patient reach of its global health flagship programs in Leprosy, Malaria, Chagas Disease and Sickle Cell Disease by at least 50% over the same time period.

The company estimates achievement of those targets to result in a potential reach of over 23 million patients across both initiatives.

The company said it also further strengthened its carbon neutrality target to aim for full carbon neutrality across its supply chain by 2030, in addition to its already stated target for carbon neutrality in its own operations by 2025.

In addition, Novartis said that it has collaborated with the African Union initiated Africa Medical Supplies Platform to support the supply of medicines from the Novartis COVID-19 Pandemic Response Portfolio. The portfolio of 15 medicines, including Dexamethasone, for symptomatic treatment of COVID-19 for LMICs was launched in July 2020 and is provided through Sandoz, the generics and biosimilar division of Novartis.

The company noted that it completed enrollment in CAN-COVID Phase III clinical trial, studying canakinumab in patients with COVID-19 pneumonia, with an expected readout in Q4 2020. Novartis also continues a Phase III clinical trial to evaluate the use of ruxolitinib in COVID-19 patients with a severe immune reaction.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bea Lydecker's Naturals, Inc. is recalling six Living Free brand dietary supplement products citing undeclared soy lecithin, the U.S. Food and Drug Administration said. According to the agency, the labels declare lecithin but do not declare soy lecithin. Investment banking major Morgan Stanley plans to block employees and clients who are not fully vaccinated against COVID-19 from entering its New York offices, the Financial Times reported citing an internal memo. The policy is expected to come into effect on July 12, and all unvaccinated employees will lose building access from then onwards. Oklahoma City, Oklahoma -based Prairie Wolf Spirits, Inc. is recalling certain Prairie Wolf Distillery hand sanitizer packaged in containers that resemble water bottles, the U.S. Food and Drug Administration said. The product poses a risk of ingestion. The recall involves all lots of Prairie Wolf Distillery hand sanitizer packaged in 16.9 fluid ounce and 20 fluid ounce containers.
Follow RTT